BIOMAT Database Logo BIOMAT Database Logo

Comparison of SARS-CoV-2 Antibody Response After 2-Dose mRNA-1273 vs BNT162b2 Vaccines in Incrementally Immunosuppressed Patients. 2022

Jonathan Mitchell, and Caoilfhionn M Connolly, and Teresa Po-Yu Chiang, and Jennifer L Alejo, and William A Werbel, and Dorry L Segev, and Allan B Massie
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000090982 BNT162 Vaccine mRNA vaccine against SARS-CoV-2 developed by Pfizer and BioNTech. Abdavomeran,BNT-162A1,BNT-162B1,BNT-162B2,BNT-162C2,BNT162A1,BNT162B1,BNT162B2,BNT162C2,COVID-19 Vaccine Pfizer-BioNTech,Comirnaty,Pfizer Covid-19 Vaccine,Pidacmeran,Tozinameran,BNT 162A1,BNT 162B1,BNT 162B2,BNT 162C2,COVID 19 Vaccine Pfizer BioNTech,Covid-19 Vaccine, Pfizer,Pfizer Covid 19 Vaccine,Pfizer-BioNTech, COVID-19 Vaccine,Vaccine Pfizer-BioNTech, COVID-19,Vaccine, BNT162,Vaccine, Pfizer Covid-19
D000090983 2019-nCoV Vaccine mRNA-1273 mRNA vaccine against SARS-CoV-2, developed by Moderna. COVID-19 Vaccine Moderna,CX-024414,Elasomeran,M-1273,Moderna COVID-19 Vaccine,Moderna COVID-19 Vaccine RNA,Moderna COVID-19 Vaccine, Bivalent,Spikevax,TAK-919,mRNA-1273,mRNA-1273.211,2019 nCoV Vaccine mRNA 1273,COVID 19 Vaccine Moderna,COVID-19 Vaccine, Moderna,CX 024414,CX024414,M 1273,M1273,Moderna COVID 19 Vaccine,Moderna COVID 19 Vaccine RNA,Moderna COVID 19 Vaccine, Bivalent,Moderna, COVID-19 Vaccine,TAK 919,TAK919,Vaccine, Moderna COVID-19,mRNA 1273,mRNA 1273.211,mRNA-1273, 2019-nCoV Vaccine
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D014612 Vaccines Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases. Vaccine

Related Publications

Jonathan Mitchell, and Caoilfhionn M Connolly, and Teresa Po-Yu Chiang, and Jennifer L Alejo, and William A Werbel, and Dorry L Segev, and Allan B Massie
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.
October 2021, JAMA,
Jonathan Mitchell, and Caoilfhionn M Connolly, and Teresa Po-Yu Chiang, and Jennifer L Alejo, and William A Werbel, and Dorry L Segev, and Allan B Massie
Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients.
March 2022, Vaccines,
Jonathan Mitchell, and Caoilfhionn M Connolly, and Teresa Po-Yu Chiang, and Jennifer L Alejo, and William A Werbel, and Dorry L Segev, and Allan B Massie
Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
December 2021, Microbiology spectrum,
Jonathan Mitchell, and Caoilfhionn M Connolly, and Teresa Po-Yu Chiang, and Jennifer L Alejo, and William A Werbel, and Dorry L Segev, and Allan B Massie
Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine.
September 2021, JAMA network open,
Jonathan Mitchell, and Caoilfhionn M Connolly, and Teresa Po-Yu Chiang, and Jennifer L Alejo, and William A Werbel, and Dorry L Segev, and Allan B Massie
Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
October 2022, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,
Jonathan Mitchell, and Caoilfhionn M Connolly, and Teresa Po-Yu Chiang, and Jennifer L Alejo, and William A Werbel, and Dorry L Segev, and Allan B Massie
Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers.
May 2022, Journal of Korean medical science,
Jonathan Mitchell, and Caoilfhionn M Connolly, and Teresa Po-Yu Chiang, and Jennifer L Alejo, and William A Werbel, and Dorry L Segev, and Allan B Massie
Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection.
May 2022, PNAS nexus,
Jonathan Mitchell, and Caoilfhionn M Connolly, and Teresa Po-Yu Chiang, and Jennifer L Alejo, and William A Werbel, and Dorry L Segev, and Allan B Massie
Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals.
December 2021, Journal of travel medicine,
Jonathan Mitchell, and Caoilfhionn M Connolly, and Teresa Po-Yu Chiang, and Jennifer L Alejo, and William A Werbel, and Dorry L Segev, and Allan B Massie
Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers.
June 2022, Viruses,
Jonathan Mitchell, and Caoilfhionn M Connolly, and Teresa Po-Yu Chiang, and Jennifer L Alejo, and William A Werbel, and Dorry L Segev, and Allan B Massie
Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2.
January 2022, Biomedicines,
Copied contents to your clipboard!